Carmenta gains licensing option for preeclampsia diagnostic tool

01/28/2013 | GenomeWeb Daily News (free registration)

Carmenta Bioscience has been granted an option to exclusively license technology from Stanford University for undisclosed terms. The Palo Alto, Calif.-based company aims to use the technology to design assays for detecting preeclampsia in pregnant women with or without symptoms of the illness, President and CEO Matthew Cooper said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI